Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)

Artiva Biotherapeutics (ARTV) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $22.9 million as the latest value for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities fell 10.73% year-over-year to $22.9 million; the TTM value through Dec 2024 reached $22.9 million, down 10.73%, while the annual FY2024 figure was $22.9 million, 10.73% down from the prior year.
  • Total Non-Current Liabilities hit $22.9 million in Q4 2024 for Artiva Biotherapeutics, down from $24.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $25.6 million in Q4 2023 and bottomed at $22.9 million in Q4 2024.